Key result
Flunarizine promotes acetylcholine receptor clustering in a dose- and agrin-dependent manner and modulates Cav3.2 at the neuromuscular junction in spinal muscular atrophy models.
Why the study?
Flunarizine was previously shown to improve neuromuscular junctions in SMA model mice, but the underlying mechanisms remained elusive.
Flunarizine promotes neuromuscular junction formation and maturation in SMA models by modulating agrin signaling and Cav3.2 channel activity.
Answers are grounded in this paper and cite their sources.
Should not change SMA practice; leaves open Cav3.2–agrin/LRP4 signaling as an adjunct NMJ target after incomplete SMN responses.
SMN protein deficiency causes motoneuron disease spinal muscular atrophy (SMA). SMN-based therapies improve patient motor symptoms to variable degrees. An early hallmark of SMA is the perturbation of the neuromuscular junction (NMJ), a synapse between a motoneuron and muscle cell. NMJ formation depends on acetylcholine receptor (AChR) clustering triggered by agrin and its co-receptors lipoprotein receptor-related protein 4 (LRP4) and transmembrane muscle-specific kinase (MuSK) signalling pathway. We have previously shown that flunarizine improves NMJs in SMA model mice, but the mechanisms remain elusive. We show here that flunarizine promotes AChR clustering in cell-autonomous, dose- and agrin-dependent manners in C2C12 myotubes. This is associated with an increase in protein levels of LRP4, integrin-beta-1 and alpha-dystroglycan, three agrin co-receptors. Furthermore, flunarizine enhances MuSK interaction with integrin-beta-1 and phosphotyrosines. Moreover, the drug acts on the expression and splicing of Agrn and Cacna1h genes in a muscle-specific manner. We reveal that the Cacna1h encoded protein Cav3.2 closely associates in vitro with the agrin co-receptor LRP4 . In vivo, it is enriched nearby NMJs during neonatal development and the drug increases this immunolabelling in SMA muscles. Thus, flunarizine modulates key players of the NMJ and identifies Ca v 3.2 as a new protein involved in the NMJ biology.
No takes yet. Share an insight, caveat, or question.
Delers et al. (2022) studied Spinal muscular atrophy. Flunarizine vs. Vehicle/DMSO was evaluated on AChR clustering and Cav3.2 channel activity. Flunarizine promotes acetylcholine receptor clustering in a dose- and agrin-dependent manner and modulates Cav3.2 at the neuromuscular junction in spinal muscular atrophy models.
Synapse has enriched 10 related papers. Consider them for comparative context: